Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rsv-604. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCKBR | P32239 | 15/20 | 0.68 |
| ▸ | CCKAR | P32238 | 8/20 | 0.64 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rsv-604 SCHEMBL29351170 | 1.00 | CCKBR (0.68) | CCKBRCCKARBDKRB1 | |
| Rsv-604 SCHEMBL641780 | 1.00 | CCKBR (0.68) | CCKBRCCKARBDKRB1 | |
| Rsv-604 SCHEMBL29670099 | 1.00 | CCKBR (0.68) | CCKBRCCKARBDKRB1 | |
| Rsv-604 SCHEMBL31143725 | 1.00 | CCKBR (0.68) | CCKBRCCKARBDKRB1 | |
| Rsv-604 SCHEMBL1016244 | 0.92 | CCKBR (0.59) | CCKBRCCKARBDKRB1 | |
| Rsv-604 SCHEMBL1016243 | 0.92 | CCKBR (0.59) | CCKBRCCKARBDKRB1 | |
| Rsv-604 SCHEMBL1015190 | 0.92 | CCKBR (0.58) | CCKBRCCKARBDKRB1 | |
| Rsv-604 SCHEMBL2203787 | 0.92 | CCKBR (0.58) | CCKBRCCKARBDKRB1 | |
| SCHEMBL644302 | 0.89 | CCKBR (0.68) | CCKBRCCKARBDKRB1 | |
| SCHEMBL642491 | 0.87 | CCKBR (0.74) | CCKBRCCKARBDKRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220363640-A1 | ANTIVIRAL COMPOUNDS | Janssen Biopharma, Inc. (US) | 2022-11-17 | — | — | US | claimed |
| CN-114716426-A | Antiviral compounds | 詹森生物制药有限公司 | 2022-07-08 | — | — | CN | claimed |
| CN-105636936-B | Antiviral compounds | 詹森生物制药有限公司 | 2022-04-05 | — | — | CN | claimed |
| US-10881666-B2 | Combination pharmaceutical agents as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2021-01-05 | — | — | US | claimed |
| EP-3687543-A1 | COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS | Enanta Pharmaceuticals, Inc. (US) | 2020-08-05 | — | — | EP | claimed |
| US-20190263754-A1 | ANTIVIRAL COMPOUNDS | ALIOS BIOPHARMA, INC. (US) | 2019-08-29 | — | — | US | claimed |
| US-10358453-B2 | Antiviral compounds | ALIOS BIOPHARMA, INC. (US) | 2019-07-23 | — | — | US | claimed |
| US-20190192535-A1 | COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2019-06-27 | — | — | US | claimed |
| WO-2019067864-A1 | COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2019-04-04 | — | — | WO | claimed |
| US-20180065932-A1 | ANTIVIRAL COMPOUNDS | ALIOS BIOPHARMA, INC. | 2018-03-08 | — | — | US | claimed |
| US-20100056500-A1 | Stable Parenteral Formulation | BURANACHOKAISAN THITIWAN | 2010-03-04 | — | — | US | claimed |
| US-20100015063-A1 | Benzodiazepine Derivatives and Pharmaceutical Compositions Containing Them | ARROW THERAPEUTICS LIMITED (GB) | 2010-01-21 | — | — | US | claimed |
| EP-2094308-A1 | STABLE PARENTERAL FORMULATION CONTAINING A RSV INHIBITOR OF A BENZODIAZEPINE STRUCTURE | Novartis AG (CH) | 2009-09-02 | — | — | EP | claimed |
| US-7582624-B2 | Benzodiazepine derivatives and pharmaceutical compositions containing them | ARROW THERAPEUTICS LIMITED (GB) | 2009-09-01 | — | — | US | claimed |
| EP-1727550-B1 | PHARMACEUTICAL COMPOSITION COMPRISING A BENZODIAZEPINE DERIVATIVE AND AN INHIBITOR OF THE RSV FUSION PROTEIN | ARROW THERAPEUTICS LTD (GB) | 2009-07-29 | — | — | EP | claimed |
| WO-2008063634-A1 | STABLE PARENTERAL FORMULATION CONTAINING A RSV INHIBITOR OF A BENZODIAZEPINE STRUCTURE | NOVARTIS AG (CH) | 2008-05-29 | — | — | WO | claimed |
| US-20070142403-A1 | Pharmaceutical composition comprising a benzodiazepine derivative and an inhibitor of the rsv fusion protein | NOVARTIS PHARMACEUTICALA CORPORATION (US) | 2007-06-21 | — | — | US | claimed |
| EP-1727550-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A BENZODIAZEPINE DERIVATIVE AND AN INHIBITOR OF THE RSV FUSION PROTEIN | Arrow Therapeutics Limited (GB) | 2006-12-06 | — | — | EP | claimed |
| US-20060040923-A1 | Benzodiazepine derivatives and pharmaceutical compositions containing them | ARROW THERAPEUTICS LIMITED (GB) | 2006-02-23 | — | — | US | claimed |
| WO-2005089769-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A BENZODIAZEPINE DERIVATIVE AND AN INHIBIT OR OF THE RSV FUSION PROTEIN | ARROW THERAPEUTICS LIMITED (GB) | 2005-09-29 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190263754-A1 | ANTIVIRAL COMPOUNDS | MAVS, SARS1, ZC3HAV1 | CCKBR 4674/4885CCKAR 4179/4885BDKRB1 4405/4885 |
| US-20100056500-A1 | Stable Parenteral Formulation | GABRA5, GABRA6, GABRP | CCKBR 1286/4885CCKAR 1548/4885BDKRB1 380/4885 |
| US-10881666-B2 | Combination pharmaceutical agents as RSV inhibitors | SERPINB1, FURIN, HIF1AN | CCKBR 3869/4885CCKAR 4257/4885BDKRB1 3048/4885 |
| US-20060040923-A1 | Benzodiazepine derivatives and pharmaceutical compositions containing them | GABRA6, CNR1, SIGMAR1 | CCKBR 195/4885CCKAR 137/4885BDKRB1 292/4885 |
| US-20220363640-A1 | ANTIVIRAL COMPOUNDS | MAVS, SARS1, ZC3HAV1 | CCKBR 4674/4885CCKAR 4179/4885BDKRB1 4405/4885 |
| US-20180065932-A1 | ANTIVIRAL COMPOUNDS | MAVS, SARS1, ZC3HAV1 | CCKBR 4674/4885CCKAR 4179/4885BDKRB1 4405/4885 |
| US-10358453-B2 | Antiviral compounds | MAVS, SARS1, ZC3HAV1 | CCKBR 4674/4885CCKAR 4179/4885BDKRB1 4405/4885 |
| US-20100015063-A1 | Benzodiazepine Derivatives and Pharmaceutical Compositions Containing Them | GABRA6, CNR1, SIGMAR1 | CCKBR 197/4885CCKAR 137/4885BDKRB1 342/4885 |
| US-20190192535-A1 | COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS | SERPINB1, FURIN, HIF1AN | CCKBR 3869/4885CCKAR 4257/4885BDKRB1 3048/4885 |
| US-20070142403-A1 | Pharmaceutical composition comprising a benzodiazepine derivative and an inhibitor of the rsv fusion protein | GABRP, TSPO, GABRA1 | CCKBR 2243/4885CCKAR 2354/4885BDKRB1 2284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.